A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump

Inclusion Criteria: * Type 1 Diabetes Mellitus for more than 12 months. * BMI between 18.5 and 28.5 kg/m². * HbA1C level \<=9.0%. * Insulin treated for at least 12 months with total insulin dose \<1.2U/kg/day. Exclusion Criteria: * Type 2 Diabetes Mellitus. * History of multiple and/or severe allergies to drugs or foods. * Any history or presence of clinically relevant cardiovascular, pulmonary, respiratory, gastrointestinal, hepatic, renal, metabolic, endocrinological (with the exception of conditions associated with diabetes mellitus), haematological, dermatological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or signs of acute illness as judged by the Investigator. * More than one episode of severe hypoglycaemia with seizure, coma or requiring assistance of another person during the past 6 months. * Proliferative retinopathy or maculopathy and/or severe neuropathy, in particular autonomic neuropathy. * Females of childbearing potential, who are pregnant, breast-feeding or intend to become pregnant or are not using highly effective contraceptive methods.